Dawn Johnstone
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 2
-
- Prostate Cancer Diagnosis and Treatment 1
- Prostate Cancer Treatment and Research 1
- Partner nations
- United KingdomAustraliaIndonesia
In The Last Decade
Dawn Johnstone
9 papers receiving 1.6k citations
Dawn Johnstone's Hit Papers
Peers
Comparison fields: 5 of 102
- Infectious Diseases 954
- Applied Microbiology and Biotechnology 50
- Neurology 339
- Internal Medicine 56
- Obstetrics and Gynecology 84
Countries citing papers authored by Dawn Johnstone
This map shows the geographic impact of Dawn Johnstone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Johnstone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Johnstone more than expected).
Fields of papers citing papers by Dawn Johnstone
This network shows the impact of papers produced by Dawn Johnstone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Johnstone. The network helps show where Dawn Johnstone may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2023 | 83 | |
| 7 | 2024 | 26 | |
| 8 | 2025 | 5 | |
| 9 | 2025 | 4 |
About Dawn Johnstone
Dawn Johnstone is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology, having authored 9 papers that have together received 1.6k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (2 papers), Sexual Differentiation and Disorders (1 paper), Hormonal and reproductive studies (1 paper), Prostate Cancer Diagnosis and Treatment (1 paper), Bladder and Urothelial Cancer Treatments (1 paper) and Prostate Cancer Treatment and Research (1 paper). The work is most often cited by research in Infectious Diseases (954 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (339 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (84 citations). Dawn Johnstone has collaborated with scholars based in United Kingdom, Australia and Indonesia. Their work appears in journals such as The Lancet, JAMA Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.